Login / Signup

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.

María N BarrachinaIrene IzquierdoLidia Hermida-NogueiraLuis A MoranAmparo PérezAna B ArroyoNuria García-BarberáRocío González-ConejeroSara TroitiñoJohannes A EbleJosé RiveraConstantino MartínezMaría I LozaEduardo DomínguezAngel Garcia
Published in: International journal of molecular sciences (2021)
Idelalisib may have antiplatelet effects with minor bleeding effects, which provides a rationale to evaluate its antithrombotic efficacy in humans.
Keyphrases
  • atrial fibrillation
  • clinical trial
  • chronic lymphocytic leukemia